Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

This randomized controlled trial will evaluate the effectiveness of neuroplasticity-targeted supplements on neuroinflammatory markers and ADHD symptoms in children aged 6 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Participants will be randomly assigned to one of four groups: gut-targeted supplements (prebiotics and probiotics), brain-targeted supplements (omega-3 fatty acids and vitamin B1), combined supplementation, or placebo. The intervention period will last 12 weeks. Primary outcomes include changes in ADHD symptom severity and clinical scores using validated rating scales. Secondary outcomes include changes in biomarkers of neuroinflammation and neuroplasticity, including IL-6, TNF-alpha, BDNF, short-chain fatty acids, and Claudin-5.

Key facts

Study ID

NCT07665658

Run by

Khyber Medical University Peshawar

People needed

68

Starts

2026-03-01

Expected to finish

2026-12-25

Last updated by the study team

2026-06-24

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-5 confirmed ADHD diagnosis
• Age 6-12 years
• Medication-free or on stable stimulant medication (≥1 month)

You may not qualify if…

• Antibiotic use in last 4 weeks
• Gastrointestinal disorders
• Neurological comorbidities (e.g., epilepsy)
• Severe food allergies

Where it is running

• Khyber Teaching Hospital — Peshawar, KPK, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.